M&G Plc Has $5.35 Million Holdings in HUTCHMED (China) Limited (NASDAQ:HCM)

M&G PLC grew its stake in shares of HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) by 98.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 267,231 shares of the company's stock after acquiring an additional 132,333 shares during the period. M&G PLC owned 0.15% of HUTCHMED worth $5,345,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. BNP Paribas Financial Markets grew its stake in shares of HUTCHMED by 54.9% in the first quarter. BNP Paribas Financial Markets now owns 42,926 shares of the company's stock valued at $721,000 after acquiring an additional 15,221 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in shares of HUTCHMED by 70.5% during the first quarter. Russell Investments Group Ltd. now owns 18,179 shares of the company's stock worth $304,000 after purchasing an additional 7,515 shares during the period. Bellevue Group AG raised its position in shares of HUTCHMED by 2.1% in the first quarter. Bellevue Group AG now owns 1,154,632 shares of the company's stock valued at $19,398,000 after buying an additional 23,521 shares in the last quarter. Hennion & Walsh Asset Management Inc. boosted its stake in shares of HUTCHMED by 8.6% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 61,887 shares of the company's stock valued at $1,060,000 after buying an additional 4,877 shares during the period. Finally, Rhumbline Advisers grew its position in HUTCHMED by 8.1% during the second quarter. Rhumbline Advisers now owns 7,553 shares of the company's stock worth $129,000 after buying an additional 564 shares in the last quarter. Institutional investors own 8.82% of the company's stock.

HUTCHMED Trading Down 4.0 %

Shares of HCM stock traded down $0.75 during trading hours on Friday, reaching $17.95. The company's stock had a trading volume of 85,779 shares, compared to its average volume of 98,757. The company has a current ratio of 2.81, a quick ratio of 2.68 and a debt-to-equity ratio of 0.07. HUTCHMED has a fifty-two week low of $11.93 and a fifty-two week high of $21.92. The firm's 50 day simple moving average is $18.74 and its 200-day simple moving average is $18.70.

Analyst Upgrades and Downgrades

HCM has been the subject of a number of recent analyst reports. StockNews.com upgraded HUTCHMED from a "hold" rating to a "buy" rating in a research report on Monday, November 4th. The Goldman Sachs Group upped their price objective on shares of HUTCHMED from $17.00 to $19.00 and gave the stock a "neutral" rating in a research report on Thursday, August 1st.

HUTCHMED Profile

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.